Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after inje...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Eli Magen, Sumit Mukherjee, Mahua Bhattacharya, Rajesh Detroja, Eugene Merzon, Idan Blum, Alejandro Livoff, Mark Shlapobersky, Gideon Baum, Ran Talisman, Evgenia Cherniavsky, Amir Dori, Milana Frenkel-Morgenstern
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2022-07-01
Serie:	Vaccines
Soggetti:	BNT162b2 mRNA vaccine COVID-19 myositis
Accesso online:	https://www.mdpi.com/2076-393X/10/7/1135
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!